Scholar Rock (SRRK) Soars 29% as Drug Candidate Progresses
In an announcement last week, Scholar Rock Holding Corp.
Scholar Rock Holding Corp (SRRK)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Siren L.L.C. Raymond Debbane | 9,250,005 | $344,470,186 | 13.48% | |
| 2. | Samsara BioCapital Srini Akkaraju And Michael Dybbs | 5,612,896 | $209,024,247 | 27.29% | |
| 3. | Redmile Group Jeremy Green | 3,904,456 | $145,401,941 | -1% | 14.15% |
| 4. | Holocene Advisors Brandon Haley | 2,461,596 | $91,669,835 | 0.21% | |
| 5. | Driehaus Capital Richard Driehaus | 2,023,959 | $75,372,233 | +72% | 0.54% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $40.97 | 4,403 | $180,390.91 | 530,038 | 2025-10-07 | Filing | |
| $40.18 | 12,400 | $498,232.00 | 525,635 | 2025-10-07 | Filing | |
| $39.31 | 12,796 | $503,010.76 | 513,235 | 2025-10-07 | Filing | |
| $39.52 | 13,748 | $543,320.96 | 500,439 | 2025-10-06 | Filing | |
| $38.68 | 80,863 | $3,127,780.84 | 486,691 | 2025-10-06 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $44.63 | 280 | $12,497.63 | 32,908 | 2025-12-16 | Filing | |
| $43.88 | 726 | $31,854.05 | 33,188 | 2025-12-16 | Filing | |
| $45.21 | 136,462 | $6,169,788.18 | 108,964 | 2025-12-04 | Filing | |
| $30.67 | 3,353 | $102,846.23 | 108,964 | 2025-09-22 | Filing | |
| $33.20 | 76 | $2,522.92 | 33,914 | 2025-09-16 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 14,012,078 | $521,809,784 | 0.03% | |
| 2. | 6,760,187 | $251,749,365 | 0% | |
| 3. | 4,914,927 | $183,031,882 | 0% | |
| 4. | 4,545,887 | $169,288,833 | 0.03% | |
| 5. | 3,763,103 | $140,137,956 | 0% |
News See All
Scholar Rock Holding Corporation (NASDAQ:SRRK) Q3 2025 Earnings Call Transcript
Scholar Rock Holding Corporation (NASDAQ:SRRK) Q3 2025 Earnings Call Transcript November 14, 2025Scholar Rock Holding Corporation misses on earnings expectations.
Scholar Rock (SRRK) Climbs 24% on Drug Candidate Progress
In an updated report, Scholar Rock Holding Corp.
Can Apitegromab Approval Turn Scholar Rock (SRRK) Into the Next Biotech Multibagger?
Scholar Rock Holding Corp. (NASDAQ:SRRK) is one of the best multibagger stocks to invest in right now.
15 Best Multibagger Stocks to Invest in Right Now
Just as a single diamond can outshine a handful of pebbles, a well-chosen multibagger can transform an ordinary portfolio into an extraordinary one.
Scholar Rock (SRRK) Jumps 14% on Bargain-Hunting, Price Down 20.4% YTD
In the second quarter of the year, Scholar Rock Holding Corp. (NASDAQ:SRRK) saw its net loss widen by 89.6 percent to $110 million from $58 million in the same period last year.
Scholar Rock's Apitegromab Maintains Lean Mass In Phase 2 EMBRAZE Trial With Tirzepatide-Induced Weight Loss
Scholar Rock Holding Corporation (NASDAQ:SRRK) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in.
11 Best GLP-1 and Weight Loss Stocks to Invest in
GLP-1 medicines are a type of prescription that mimics a natural hormone that regulates blood sugar and appetite.
Scholar Rock Holding Corporation (NASDAQ:SRRK) Q2 2025 Earnings Call Transcript
Scholar Rock Holding Corporation (NASDAQ:SRRK) Q2 2025 Earnings Call Transcript August 6, 2025Scholar Rock Holding Corporation misses on earnings expectations.
Scholar Rock (SRRK) Jumps 16.6% After Successful Weight Loss Drug Trial
In a statement, Scholar Rock Holding Corporation (NASDAQ:SRRK) said the trial, which aims to assess its drug candidate apitegromab’s combination with tirzepatide, was generally well tolerated, leading...
Hedge Fund Resource Center Billionaire Hedge Funds
